Analyst firm HC Wainwright raises Q2 2024 EPS estimates for SpringWorks Therapeutics (SWTX) from ($1.01) to ($0.99) with a "Buy"

HC Wainwright raises Q2 2024 EPS estimates for SpringWorks Therapeutics (SWTX) from ($1.01) to ($0.99) with a "Buy" rating and $74.00 price target. The consensus full-year earnings estimate is ($4.68) per share. For Jasper Therapeutics (JSPR), HC Wainwright anticipates Q1 2024 EPS of ($1.43) with a "Buy" rating and $65.00 target price. Consensus full-year earnings estimate is ($5.00) per share.

May 11, 2024
3 Articles

Further Reading